European Medicines Agency recommends restricting the use of oral moxifloxacin-containing medicines

European Medicines Agency (EMEA)Finalising a review of the safety of moxifloxacin-containing medicines for oral use, the European Medicines Agency (EMEA) has concluded that these medicines should only be prescribed in the treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis and community-acquired pneumonia when other antibiotics cannot be used or have failed. The Agency also recommended strengthening the warnings for oral moxifloxacin medicines.

Moxifloxacin is a fluoroquinolone antibiotic. Oral formulations of medicines containing moxifloxacin are authorised at the level of the Member States in the European Union (EU) under several trade names for the treatment of acute exacerbation of chronic bronchitis, community-acquired pneumonia, acute bacterial sinusitis and, in some Member States, for mild to moderate pelvic inflammatory disease.

The EMEA's Committee for Medicinal Products for Human Use (CHMP) has reviewed all available information on the safety of moxifloxacin-containing medicines for oral use, following concerns over their liver safety when used for acute bacterial sinusitis, acute exacerbation of chronic bronchitis and community-acquired pneumonia.

At its July 2008 meeting, the CHMP concluded that the benefits of oral moxifloxacin medicines continue to outweigh its risks. However, due to safety concerns, mainly related to an increased risk of adverse hepatic reactions, the CHMP recommended restricting their use in these indications. For acute bacterial sinusitis and acute exacerbations of chronic bronchitis, they should only be prescribed when other antibiotics cannot be used or have failed. For community acquired pneumonia, they should only be given when treatment with other antibiotics cannot be used.

The CHMP also recommended that the warnings of oral moxifloxacin-containing medicines should be strengthened concerning the risk of diarrhoea, heart failure in women and older patients, severe skin reactions and fatal liver injury.

Doctors are advised to prescribe oral moxifloxacin-containing medicines according to the updated product information and to consider the official guidance on the appropriate use of the antibiotics and the local prevalence of resistance. Patients should speak to their doctor or pharmacist if they have any questions.

The CHMP opinion will now be forwarded to the European Commission for the adoption of a decision applicable to all oral moxifloxacin-contain medicines authorised in the EU.

For further information, please visit:
http://www.emea.europa.eu

Most Popular Now

How SARS-CoV-2 mutates to escape antibody binding

In a recurring pattern of evolution, SARS-CoV-2 evades immune responses by selectively deleting small bits of its genetic sequence, according to new research from the Uni...

Anticancer drug may improve outcome for severe COV…

Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China ...

Pfizer and BioNTech commence global clinical trial…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in a global Phase 2/3 study to further evaluate the saf...

GSK and Vir Biotechnology expand coronavirus colla…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) have signed a binding agreement to expand their existing collaboration to include the resear...

One dose of COVID-19 vaccine provokes strong immun…

Although clinical trial data are encouraging, real-world evidence with regard to the COVID-19 vaccine remains scarce. In particular, response to the vaccine among those p...

Johnson & Johnson announces submission of appl…

Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting E...

Could a nasal spray prevent coronavirus transmissi…

A nasal antiviral created by researchers at Columbia University Vagelos College of Physicians and Surgeons blocked transmission of SARS-CoV-2 in ferrets, suggesting the n...

European Commission purchases additional 150 milli…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission purchased an...

Johnson & Johnson Announces Submission to Worl…

Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization...

Neandertal gene variants both increase and decreas…

Last year, researchers at Karolinska Institutet in Sweden and the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany showed that a major genetic risk ...

CureVac initiates rolling submission with European…

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today annou...

Pfizer and BioNTech publish data from in vitro stu…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication in Nature Medicine of data from in vitro studies that demonstrate that sera from in...